He Doesn’t Have Time to Wait.

When faced with a negative or equivocal PSMA PET scan, don’t hesitate to make Axumin your immediate next step.

Confidence. Confirmed.

Why Axumin?

Not an actual patient.

Axumin excels at prostate cancer detection^1,2

Examine efficacy data

Get reimbursement and formulary support

See resources

Prostate cancer recurrence with negative PSMA is a real concern

Up to 42% of biochemically recurrent prostate cancer is PSMA negative.³ Axumin doesn’t rely on PSMA expression. See how it detects what PSMA PET agents may not.¹

Explore the MOA

Image courtesy of Blue Earth Diagnostics.

Reliable detection when it matters most

Prostate cancer recurrence requires fast action. When facing a negative or equivocal PSMA PET scan, choose the agent with efficacy that ensures confidence.⁴

See the Data

Axumin plays a vital role in shaping treatment plans

When quick and decisive action is needed, Axumin provides the details physicians need to make informed choices faster.^1,4

See How

Utilize our reimbursement and formulary support offerings

Reference a suite of services and downloadable resources, including coding information, checklists, and sample forms.

Get Support

MOA=mechanism of action; PET=positron emission tomography; PSMA=prostate-specific membrane antigen.

References: 1. Axumin. Package insert. Blue Earth Diagnostics Ltd; 2022. 2. Pernthaler B, Kulnik R, Gstettner C, Salamon S, Aigner RM, Kvaternik H. A prospective head-to-head comparison of ¹⁸F-fluciclovine with ⁶⁸Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT. Clin Nucl Med. 2019;44(10):e566-e573. 3. Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469-478. doi:10.1016/j.eururo.2019.06.030 4. Mallak N, Obala G, Lim JY. Role of ¹⁸F-fluciclovine PET/CT in patients with biochemical recurrence of prostate cancer and a negative PSMA PET/CT. Presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference; June 21-24, 2025; New Orleans, LA.

INDICATION | IMPORTANT SAFETY INFORMATION

INDICATION

Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Axumin full Prescribing Information.